Chordate Medical Holding (publ) ("Chordate", "The Company") publishes its year-end report for 2021 on Friday, February 25, 2022, at 08:30CET. On Monday, February 28 at 11:00CET, The Company invites to a webcast teleconference with CEO Anders Weilandt. The conference is followed by a question-and-answer session. The presentation will be held in English. You can follow the conference via computer or mobile devices.
To register for the web conference, register via the following link: https://attendee.gotowebinar.com/register/5782743288792495628
The number of places is limited, so we recommend registering well in advance to secure a place.
A recording of the web conference will be available after the conference on the company's website www.chordate.com and on Västra Hamnen Corporate Finance's YouTube channel.
For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277
The following documents can be retrieved from beQuoted
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com
Chordate's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vastra Hamnen Corporate Finance AB, +46 40 200 250, email@example.com.